Varsal Tech develops and sells pharmaceutical intermediates and specialty chemicals for the pharmaceutical, electronics, personal care, and industrial sectors. The company’s core business focuses on pharmaceutical intermediates, which are chemical building blocks used to produce active pharmaceutical ingredients. Its flagship product is Toluenesulfonylmethyl isocyanide (TMC), and it also sells sulfonyl and phosphorous chemicals. Varsal operates an asset-light business model as an intermediary and technology provider. The company does not own manufacturing facilities; instead, it develops proprietary chemical processes and directs third-party manufacturers in China to produce goods according to its specifications. Varsal then resells these products and manages the international logistics of hazardous materials. The company's customer base is highly concentrated, with two entities accounting for the vast majority of revenue. High switching costs and regulatory requirements, such as GMP compliance and FDA qualification, embed Varsal's products into customer supply chains. To reduce its reliance on Chinese manufacturing and mitigate tariff pressures, Varsal intends to acquire U.S. manufacturing assets and build a chemical plant in Saudi Arabia using proprietary technology and local financing.